Clinical trial

Strategy to Adapt Botulinum Toxin Doses in Dystonia

Name

2023PI187

Description

The study is designed to observ and collect the doses of botulinum toxin injected in dystonia in different centres to compare the initial dose and the dose recommended. We we ll study the increase of the dose injected over the time, the side effects... The hypothesis is that we inject smaller doses than we could regarding the recommandations

Trial arms

Trial start

2024-05-01

Estimated PCD

2024-05-01

Trial end

2024-06-01

Status

Not yet recruiting

Treatment

Botulinum toxin

Botulinum toxin doses injected in dystonia

Other names:

onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA

Size

100

Primary endpoint

First dose of botulinum toxin injected, U

30 years

Eligibility criteria

Inclusion Criteria: * patients over 18 years old followed for dystonia and treated with botulinum toxin Exclusion Criteria: * first dose of botulinum toxin not available

Protocol

{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}}

Updated at

2024-04-26

1 organization

1 product

1 indication

Organization

Central Hospital

Product

Botulinum toxin

Indication

Dystonia